Auckland City Hospital, Private Bag 92024, Auckland, New Zealand.
Clin Nutr. 2012 Feb;31(1):30-4. doi: 10.1016/j.clnu.2011.09.009. Epub 2011 Oct 4.
BACKGROUND & AIMS: Central venous access device (CVAD)-related complications such as catheter-related sepsis, occlusion and breakage contribute to both mortality and morbidity in home parenteral nutrition (HPN) patients. Prospectively collected data in these patients are scarce.
Data on all CVAD-related complications in four tertiary referral centres in Australia and New Zealand were prospectively collected between 01/01/2009 and 31/12/2009 together with costs of each episode that required admission.
Of 53 patients (42 adults and 11 children), 27 suffered a total of 49 episodes of CVAD-associated complications (line infection 36, catheter blockage 5, line fracture 1, line migration 7), giving an incidence of 3.6 per 1000 CVAD days (11.6 per 1000 in patients with a multi-use CVAD). Thirty seven episodes resulted in hospital admission for a median duration of 8 days (range 1-29). Responsible microbes were mainly enteric with klebsiella being the most commonly isolated organism (10 episodes). The average cost of care per episode of CVAD-associated complication requiring inpatient admission was $A9,710 (€6480 approximately).
CVAD complications, in particular line infection are still a major source of potentially avoidable HPN morbidity and mortality with a high cost to the healthcare system. The predominance of enteric organisms in our series raises the possibility of bacterial translocation as a significant component of the pathogenesis of line sepsis in HPN patients.
中心静脉置管(CVAD)相关并发症,如导管相关败血症、阻塞和断裂,导致接受家庭肠外营养(HPN)的患者死亡率和发病率上升。这些患者的前瞻性数据很少。
2009 年 1 月 1 日至 2009 年 12 月 31 日,在澳大利亚和新西兰的 4 个三级转诊中心前瞻性收集了所有与 CVAD 相关的并发症的数据,同时收集了每个需要入院治疗的并发症的费用。
53 名患者(42 名成人和 11 名儿童)中,27 名患者共发生 49 次 CVAD 相关并发症(导管感染 36 次,导管阻塞 5 次,导管断裂 1 次,导管移位 7 次),每 1000 个 CVAD 日发生 3.6 次(多用途 CVAD 患者为每 1000 例 11.6 次)。37 例因并发症住院,平均住院时间为 8 天(范围为 1-29 天)。致病微生物主要是肠道微生物,其中克雷伯菌是最常见的分离菌(10 例)。需要住院治疗的 CVAD 相关并发症的每个病例的平均护理费用为 9710 澳元(约合 6480 欧元)。
CVAD 并发症,特别是导管感染,仍然是 HPN 发病率和死亡率的主要潜在可避免原因,对医疗保健系统造成了高成本。在我们的系列研究中,肠道微生物的优势存在提示细菌易位可能是 HPN 患者导管感染发病机制的一个重要组成部分。